Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 2, pp 503–517 | Cite as

Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease

  • James R. IrwinEmail author
  • Emma Ferguson
  • Lisa A. Simms
  • Katherine Hanigan
  • James D. Doecke
  • Daman Langguth
  • Ashley Arnott
  • Graham Radford-Smith
Original Article

Abstract

Background and Aims

Patients with inflammatory bowel disease (IBD) often have subjective symptoms for months or years prior to their diagnosis. Blood tests taken prior to diagnosis may provide objective evidence of duration of pre-diagnosis disease. We aim to describe the pre-diagnosis laboratory pattern of patients with IBD.

Methods

A total of 838 patients diagnosed with IBD between 01/01/1996 and 01/03/2014, with pre-diagnosis laboratory testing available, contributed data for analysis. C-reactive protein, erythrocyte sedimentation rate, hemoglobin level, mean cell volume (MCV) platelet count, white blood cell count, neutrophil count, albumin level, ferritin level, serum iron level, alanine transaminase level, and fecal calprotectin were examined in the 24 months leading up to diagnosis and compared to baseline data taken between 24 and 36 months prior to diagnosis.

Results

For patients with Crohn’s disease, a significant drop in serum albumin and MCV levels and a significant rise in platelet count were observed between 115 and 385 days prior to diagnosis (p < 0.01, two-tailed t test). For patients with ulcerative colitis, a significant change in albumin level, MCV, hemoglobin level, platelet count, and serum iron level was observed at diagnosis (p < 0.01, two-tailed t test) but was not detectable before.

Conclusions

These data provide objective evidence of duration of delay between disease onset and diagnosis in a cohort of patients with IBD. Expediting diagnostic testing in patients presenting with symptoms consistent with IBD, who also have abnormal laboratory results, may reduce diagnostic delay, speed access to therapy, and improve clinical outcomes.

Keywords

Crohn’s disease Biomarker Pre-diagnosis 

Abbreviations

ALT

Alanine transaminase

CRP

C-reactive protein

ESR

Erythrocyte sedimentation rate

IBD

Inflammatory bowel diseases

MCV

Mean cell volume

WBC

White blood cell count

Notes

Author’s contribution

JRI performed data collection, performed statistical analysis, drafted the manuscript, and was involved in the final review of the manuscript. GRS performed data collection and was involved in the final review of the manuscript. JDD performed statistical analysis and was involved in the final review of the manuscript. EF, KH, LAS, AA, and DL performed data collection and were involved in review of the manuscript.

Funding

This work was supported by peer-reviewed grants from the National Health and Medical Research Council (Australia) and the Royal Brisbane and Women’s Hospital Foundation.

Compliance with ethical standards

Conflict of interest

GRS has worked on advisory boards for and received consulting fees from Abbvie, Janssen, Ferring, Takeda, and Amgen. JRI, EF, KH, LAS, JD, DL, and AA have no conflict of interest to declare.

References

  1. 1.
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.CrossRefGoogle Scholar
  2. 2.
    Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.  https://doi.org/10.1016/j.crohns.2009.12.003.CrossRefGoogle Scholar
  3. 3.
    Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010;4:28–62.  https://doi.org/10.1016/j.crohns.2009.12.002.CrossRefGoogle Scholar
  4. 4.
    Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation. Gastrointest Endosc. 1983;29:195–197.CrossRefGoogle Scholar
  5. 5.
    Schumacher G, Sandstedt B, Kollberg B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. Scand J Gastroenterol. 1994;29:265–274.CrossRefGoogle Scholar
  6. 6.
    Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:496–505.  https://doi.org/10.1002/ibd.21719.CrossRefGoogle Scholar
  7. 7.
    Nguyen VQ, Jiang D, Hoffman SN, et al. Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease Cohort. Inflamm Bowel Dis. 2017;23:1825–1831.  https://doi.org/10.1097/mib.0000000000001257.CrossRefGoogle Scholar
  8. 8.
    Sorrentino D. Preclinical and undiagnosed Crohn’s disease: The submerged Iceberg. Inflamm Bowel Dis. 2016;22:476–486.  https://doi.org/10.1097/MIB.0000000000000612.CrossRefGoogle Scholar
  9. 9.
    Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43:1300–1310.  https://doi.org/10.1111/apt.13641.CrossRefGoogle Scholar
  10. 10.
    Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–1122.  https://doi.org/10.1136/gut.2003.030734.CrossRefGoogle Scholar
  11. 11.
    Israeli E, Grotto I, Gilburd B, et al. Anti-saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–1236.  https://doi.org/10.1136/gut.2004.060228.CrossRefGoogle Scholar
  12. 12.
    Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, Chan AT. Association between circulating levels of C-reactive protein and Interleukin-6 and risk of inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:818–824.e6.  https://doi.org/10.1016/j.cgh.2016.01.016.Google Scholar
  13. 13.
    Karlson EW, Chibnik LB, Tworoger SS, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009;60:641–652.  https://doi.org/10.1002/art.24350.CrossRefGoogle Scholar
  14. 14.
    Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–1284.Google Scholar
  15. 15.
    del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239–1244.CrossRefGoogle Scholar
  16. 16.
    Jónsson T, Thorsteinsson J, Kolbeinsson A, Jónasdóttir E, Sigfússon N, Valdimarsson H. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis. 1992;51:863–868.CrossRefGoogle Scholar
  17. 17.
    Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996;9:379–383.CrossRefGoogle Scholar
  18. 18.
    R Core Team. R: A Language and Environment for Statistical Computing, R version 3.4.4. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 12 Nov 2018.
  19. 19.
    Zeileis A, Grothendieck G. zoo: S3 Infrastructure for regular and irregular time series. J Stat Softw. 2005;14:1–27.  https://doi.org/10.18637/jss.v014.i06.CrossRefGoogle Scholar
  20. 20.
    Champely S. PWR: Basic Functions for Power Analysis, R package version 1.2-1; 2017. https://CRAN.R-project.org/package=pwr. Accessed 12 Nov 2018.
  21. 21.
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988.Google Scholar
  22. 22.
    Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol. 2001;96:1541–1546.  https://doi.org/10.1111/j.1572-0241.2001.03755.x.CrossRefGoogle Scholar
  23. 23.
    Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol. 2011;46:304–309.  https://doi.org/10.3109/00365521.2010.533382.CrossRefGoogle Scholar
  24. 24.
    OECD Statistics. http://stats.oecd.org/. Accessed June 20, 2017.
  25. 25.
    Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74:e12.  https://doi.org/10.1136/annrheumdis-2013-204867.CrossRefGoogle Scholar
  26. 26.
    Inflammatory bowel disease|Guidance and guidelines|NICE. https://www.nice.org.uk/guidance/qs81. Accessed June 21, 2016.
  27. 27.
  28. 28.
    Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.  https://doi.org/10.1053/j.gastro.2011.01.055.CrossRefGoogle Scholar
  29. 29.
    Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn’s disease-Are we there yet? World J Gastroenterol WJG. 2006;12:7097–7103.  https://doi.org/10.3748/wjg.v12.i44.7097.CrossRefGoogle Scholar
  30. 30.
    Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107:1399–1406.  https://doi.org/10.1038/ajg.2012.196.CrossRefGoogle Scholar
  31. 31.
    Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80:1342–1352.CrossRefGoogle Scholar
  32. 32.
    Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325–333.  https://doi.org/10.1111/j.1440-1746.2009.06140.x.CrossRefGoogle Scholar
  33. 33.
    Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.CrossRefGoogle Scholar
  34. 34.
    Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol. 2008;43:961–966.CrossRefGoogle Scholar
  35. 35.
    Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007;52:1044–1050.  https://doi.org/10.1016/j.eururo.2006.12.017.CrossRefGoogle Scholar
  36. 36.
    Heianza Y, Arase Y, Fujihara K, et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: The Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care. 2012;35:1050–1052.  https://doi.org/10.2337/dc11-1793.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Inflammatory Bowel Diseases Research GroupQIMR Berghofer Medical Research InstituteBrisbaneAustralia
  2. 2.Department of Gastroenterology and HepatologyRoyal Brisbane and Women’s HospitalBrisbaneAustralia
  3. 3.School of MedicineThe University of QueenslandBrisbaneAustralia
  4. 4.CSIRO Health and Biosecurity/Australian E-Health Research CentreBrisbaneAustralia
  5. 5.Department of ImmunologySullivan and Nicolaides PathologyBrisbaneAustralia
  6. 6.Palmerston North HospitalPalmerston NorthNew Zealand

Personalised recommendations